OS Therapies Incorporated (OSTX) ニュース

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Focus of work at JLABS on tunable Antibody Drug Conjugate linker-based platform OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the...

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC...

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and...

Form CERT - Certification by an exchange approving securities for listing

Form 8-A12B - Registration of securities [Section 12(b)]

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

10 of 12 patients treated in HER2 expressing solid tumor Phase 1b trial were breast cancer patients Dose selected for ongoing Phase 2b clinical...

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

1-year Event Free Survival (EFS) of 32.5% vs. 20% 1-year EFS for comparator Interim 1-year and 18-month Overall Survival (OS) of 90.4% 0 Grade...